The primary objective of this study is to determine the safety of recombinant candidate HIV gp160 and gp120 vaccines, and their adjuvants, in HIV infected children more than 1 month of age. The secondary objective is to evaluate the immunogenicity of the vaccine candidates and their effects on virological and clinical measures.
Showing the most recent 10 out of 455 publications